Flamel Technologies S.A. (ADR)  

(Public, NASDAQ:FLML)   Watch this stock  
Find more results for FLML
+0.35 (2.29%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.95 - 15.70
52 week 9.30 - 19.50
Open 15.22
Vol / Avg. 238,747.00/480,229.00
Mkt cap 604.30M
P/E     -
Div/yield     -
EPS -1.55
Shares 38.61M
Beta 0.95
Inst. own 66%
Mar 23, 2015
Full Year 2014 Flamel Technologies SA Earnings Release (Estimated) Add to calendar
Mar 10, 2015
Flamel Technologies SA at ROTH Conference - 1:00PM EDT - Add to calendar
Feb 11, 2015
Flamel Technologies SA at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -142.94% -191.26%
Operating margin -239.33% -222.94%
EBITD margin - -83.93%
Return on average assets - -36.76%
Return on average equity - -408.97%
Employees 246 -
CDP Score - -


33, avenue du Dr. Georges Levy, Venissieux Cedex, PARC CLUB DU MOULIN A VENT
+33-4-72783434 (Phone)
+33-4-72783435 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Flamel Technologies SA is a pharmaceutical company. The Company�s focus is on the development of safer and more efficacious formulations and other medical needs in the process. Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Company�s products include Bloxiverz and Coreg CR. Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Coreg CR, the lead product using the Company�s Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate), a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors.

Officers and directors

Stephen H. Willard Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Michael S. Anderson Chief Executive Officer, Director
Bio & Compensation  - Reuters
Sian Crouzet Principal Financial Officer
Bio & Compensation  - Reuters
Rafael Jorda Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Steven A. Lisi Senior Vice President - Business and Corporate Development
Bio & Compensation  - Reuters
Gregg Stetsko Ph.D. Vice President - Research & Development
Bio & Compensation  - Reuters
Catherine Castan Director - Micropump Platform (Oral Drugs) and Intellectual Property
Bio & Compensation  - Reuters
Christian Kalita Pharmacist and Director - Quality Assurance and Regulatory Affairs
Bio & Compensation  - Reuters
Elie Vannier Director
Age: 64
Bio & Compensation  - Reuters
Catherine Brechignac PH.D Independent Director
Bio & Compensation  - Reuters